Last edition
News about "Jian Peng"
Earendil Labs Raises USD 787 Million to Scale AI-Driven Biologics Discovery
Earendil Labs will use its USD 787 million financing to scale its Artificial Intelligence (AI)-driven R&D platform, expand inter-disciplinary teams and advance a pipeline of antibody and biologics programmes targeting serious diseases.
Jian Peng | 21/03/2026 | By News Bureau | 256
Earendil Labs and WuXi Biologics Partner on Bispecific Antibodies and ADCs
Under the agreement, WuXi Biologics will provide end-to-end development and manufacturing services to Earendil Labs, supporting faster regulatory timelines, reliable CMC execution, and scalable global clinical development.
Jian Peng | 13/03/2026 | By News Bureau | 112
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy